Rockland Trust’s AbbVie ABBV Stock Holding History

Rockland Trust’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.48M	Sell	25,770 -1,128	-4%	-$243K	0.25%	78
2026 Q1	$5.85M	Sell	26,898 -497	-2%	-$110K	0.23%	80
2025 Q4	$6.26M	Buy	27,395 +254	+0.9%	+$57.9K	0.25%	79
2025 Q3	$6.28M	Sell	27,141 -414	-2%	-$84.3K	0.26%	82
2025 Q2	$5.11M	Sell	27,555 -4,239	-13%	-$788K	0.25%	75
2025 Q1	$6.66M	Sell	31,794 -690	-2%	-$134K	0.33%	68
2024 Q4	$5.77M	Sell	32,484 -2,800	-8%	-$515K	0.29%	67
2024 Q3	$6.97M	Sell	35,284 -10,607	-23%	-$1.98M	0.34%	68
2024 Q2	$7.87M	Buy	45,891 +1,009	+2%	+$167K	0.42%	65
2024 Q1	$8.17M	Sell	44,882 -1,207	-3%	-$208K	0.43%	66
2023 Q4	$7.14M	Sell	46,089 -231	-0.5%	-$33.7K	0.39%	64
2023 Q3	$6.9M	Buy	46,320 +91	+0.2%	+$13.4K	0.42%	66
2023 Q2	$6.23M	Buy	46,229 +142	+0.3%	+$20.8K	0.37%	72
2023 Q1	$7.34M	Sell	46,087 -368	-0.8%	-$56.3K	0.46%	66
2022 Q4	$7.51M	Buy	46,455 +94	+0.2%	+$14.4K	0.48%	68
2022 Q3	$6.22M	Sell	46,361 -282	-0.6%	-$40.5K	0.44%	68
2022 Q2	$7.14M	Buy	46,643 +1,505	+3%	+$230K	0.49%	64
2022 Q1	$7.32M	Buy	45,138 +137	+0.3%	+$19.9K	0.47%	62
2021 Q4	$6.09M	Buy	45,001 +2,198	+5%	+$260K	0.39%	69
2021 Q3	$4.62M	Buy	42,803 +731	+2%	+$83.5K	0.32%	71
2021 Q2	$4.74M	Sell	42,072 -994	-2%	-$112K	0.33%	73
2021 Q1	$4.66M	Buy	43,066 +8	+0%	+$856	0.34%	71
2020 Q4	$4.61M	Sell	43,058 -52	-0.1%	-$5K	0.36%	69
2020 Q3	$3.78M	Sell	43,110 -4,122	-9%	-$388K	0.32%	71
2020 Q2	$4.64M	Buy	47,232 +2,004	+4%	+$176K	0.42%	67
2020 Q1	$3.45M	Buy	45,228 +12,222	+37%	+$1.04M	0.35%	68
2019 Q4	$2.92M	Buy	33,006 +3,579	+12%	+$297K	0.24%	79
2019 Q3	$2.17M	Buy	29,427 +9,595	+48%	+$658K	0.2%	83
2019 Q2	$1.44M	Buy	19,832 +2,532	+15%	+$199K	0.14%	101
2019 Q1	$1.39M	Buy	17,300 +2,070	+14%	+$169K	0.15%	96
2018 Q4	$1.4M	Buy	15,230 +3,773	+33%	+$332K	0.17%	96
2018 Q3	$1.08M	Buy	11,457 +70	+0.6%	+$6.64K	0.13%	102
2018 Q2	$1.05M	Sell	11,387 -1,074	-9%	-$105K	0.14%	102
2018 Q1	$1.18M	Sell	12,461 -70	-0.6%	-$7.69K	0.16%	95
2017 Q4	$1.21M	Buy	12,531 +190	+2%	+$17.9K	0.16%	91
2017 Q3	$1.1M	Sell	12,341 -550	-4%	-$41.9K	0.16%	85
2017 Q2	$935K	Sell	12,891 -22,576	-64%	-$1.52M	0.15%	91
2017 Q1	$2.31M	Sell	35,467 -7,189	-17%	-$452K	0.36%	63
2016 Q4	$2.67M	Buy	42,656 +944	+2%	+$57.6K	0.43%	60
2016 Q3	$2.63M	Buy	41,712 +1,653	+4%	+$107K	0.46%	58
2016 Q2	$2.48M	Buy	40,059 +2,281	+6%	+$139K	0.43%	58
2016 Q1	$2.16M	Buy	37,778 +4,599	+14%	+$256K	0.39%	60
2015 Q4	$1.97M	Buy	33,179 +1,795	+6%	+$103K	0.35%	64
2015 Q3	$1.71M	Buy	31,384 +972	+3%	+$63.3K	0.34%	63
2015 Q2	$2.04M	Buy	30,412 +1,620	+6%	+$106K	0.41%	54
2015 Q1	$1.69M	Sell	28,792 -439	-2%	-$26.5K	0.36%	58
2014 Q4	$1.91M	Sell	29,231 -40	-0.1%	-$2.52K	0.39%	57
2014 Q3	$1.69M	Sell	29,271 -1,595	-5%	-$88.6K	0.37%	54
2014 Q2	$1.74M	Sell	30,866 -17,299	-36%	-$908K	0.4%	48
2014 Q1	$2.48M	Sell	48,165 -455	-0.9%	-$23K	0.58%	42
2013 Q4	$2.57M	Buy	48,620 +2,909	+6%	+$143K	0.62%	43
2013 Q3	$2.04M	Buy	45,711 +1,221	+3%	+$54.1K	0.54%	45
2013 Q2	$1.84M	Buy	+44,490	New	+$1.95M	0.51%	47

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Rockland Trust's ABBV Position: Q2 2026 in Review

Rockland Trust reduced its AbbVie (ABBV) stake by 4.2% in Q2 2026, selling an estimated $243K and leaving 25,770 shares worth $6.48M. The position accounts for 0.25% of the portfolio, ranked #78.

Rockland Trust first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $8.17M in Q1 2024. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Rockland Trust held 25,770 shares of AbbVie worth $6.48M as of Q2 2026.
Rockland Trust sold 1,128 AbbVie shares in Q2 2026, an estimated $243K.
AbbVie made up 0.25% of Rockland Trust's portfolio in Q2 2026, its #78 holding.
Rockland Trust first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
Rockland Trust's AbbVie position peaked at $8.17M in Q1 2024.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Rockland Trust's 13F filing for Q2 2026, filed 8 Jul 2026.